Key Highlights: Implications: Nubeqa’s India approval intensifies mHSPC competition against Janssen’s Erleada, amid prostate therapeutics market growing at 8.2% CAGR to $739M by 2030. ...
Key Highlights: Implications: Durvalumab storms earlier gastric cancer treatment, snatching share from chemo-only protocols as oncologists embrace immunotherapy combo superiority.&nb...
Key Highlights: Implications: Lantern’s Bengaluru expansion accelerates U.S. biotech offshoring of AI-drug discovery to India, intensifying talent competition with Dr. Reddy’s and Biocon w...
